Qili Qiangxin Capsule

Qili Qiangxin capsules——effective in treating chronic heart failure

 Heart failure is the ultimate cause of death for all kinds of heart diseases in the late stage. Few great breakthroughs have been obtained over the past two decades, and the research and development of effective drugs for the treatment of heart failure is still a major topic in the international medical community. Researched and developed under the guidance of Collateral Disease Theory, Qili Qiangxin Capsule has been widely researched to compare with western medicine and the results have showed that it has the comprehensive effects of first-line and second-line western medicines, and also the unique advantages by reducing myocardial cell apoptosis and improving energy metabolism.

● It has similar cardiotonic effect to Digoxins.

● It has better effect to reduce kidney aquaporin-2 than Furosemide.

● It has better effect to inhibit AngII than Ramipril.

● It has better effect to inhibit ventricular remodeling than Metoprolol.

● Reduce the apoptosis and autophagy of cardiomyocytes

● Promote cardiomyocyte proliferation

● Improve myocardial energy metabolism

● Treat arrhythmia

 A new patent drug for treating chronic heart failure in terms of both symptoms and root causes——Qili Qiangxin capsules

Qili Qiangxin Capsule, successfully developed by the National 863 Program, has brought a new hope for the drug treatment of patients with chronic heart failure. The clinical evidence-based research paper published in the Journal of the American College of Cardiology (JACC) is the most influential SCI paper in terms of the clinical research on TCM medicines. Extensive experimental studies have revealed the pharmacodynamic mechanism of Qili Qiangxin Capsule. The high attention of the international medical community has showed the important clinical value and broad market prospect of this drug in the treatment of chronic heart failure.

Qili Qiangxin Capsules Listed in Guidelines/Expert Consensus

Chinese Medical Association "Guidelines for the Diagnosis and Treatment of Heart Failure in China" 2018

Chinese Medical Association "Guidelines for the Diagnosis and Treatment of Dilated Cardiomyopathy in China" 2018

National Health Commission's "Guidelines for Reasonable Use of Drugs in Heart Failure" 2019

China Heart Failure Center Alliance (Expert Recommendations for Early Prevention and Treatment of Diastolic Heart Failure) 2021

2016 Consensus of Experts on the Diagnosis and Treatment of Chronic Heart Failure by Integrating Traditional Chinese and Western Medicine of the Chinese Association of Integrated Traditional Chinese and Western Medicine

A. A multicenter, randomized, placebo-controlled trial involving 23 centers, randomly selected 512 patients for a total of 12 weeks, with a decrease in NT proBNP level as the main evaluation indicator. The results showed that the combination of traditional Chinese medicine Qili Qiangxin Capsule on the basis of standard treatment significantly reduced the NT proBNP level in patients with chronic heart failure compared to the control group, and improved the secondary evaluation indicator, namely NYHA heart function grading Cardiovascular composite endpoint events (death, cardiac arrest followed by cardiopulmonary resuscitation, admission due to heart failure, need for intravenous medication for worsening heart failure, abandonment of treatment by patients with worsening heart failure), 6-minute walking distance, and Minnesota quality of life [1]. We look forward to conducting research with mortality as the primary endpoint to provide convincing clinical evidence. The combination of traditional Chinese and Western medicine treatment should pay attention to potential adverse reactions caused by the interaction between traditional Chinese and Western medicine.

--Extracted from "Chinese Guidelines for the Diagnosis and Treatment of Heart Failure, 2018"

Chinese Society of Cardiology Heart Failure Group/Chinese Physicians Association Heart Failure Professional Committee/Chinese Journal of Cardiology Editorial Committee

B. Qiliqianxin: In a multicenter randomized clinical study, 512 CHF patients (with DCH accounting for more than 50%) received treatment with Qiliqianxin capsule and placebo for 12 weeks, respectively. The average NT-proBNP water level in both groups decreased significantly, but the Qiliqianxin capsule group significantly reduced NT-proBNP levels by at least 30% (47.95%: 31.98%, P=0.002) compared to the placebo group. The results of this study have been validated by other clinical trials (Class Ia recommendation, Class B evidence).

The traditional Chinese medicine Minlao Qiangxin Capsule has the effect of immune regulation and improving cardiac function in the treatment of newly diagnosed DCM patients [3]. Traditional Chinese medicine such as Codonopsis pilosula, Huanghe, and Pueraria lobata have the effect of reducing the expression of inflammatory factors in DCM plasma and improving cardiac function [4-5]. It is recommended for early immunomodulatory treatment of DCM (Class Ia recommendation, Level B evidence). Usage: Lao Qiangxin Capsule 1.2 gtid; Early and long-term treatment is recommended. Further exploration is needed for the immunomodulatory therapy of DCM patients.

A multicenter randomized double-blind placebo-controlled clinical trial - QLQX-DCM study in standardized treatment of heart failure (ACEI/ARB β On the basis of receptor blockers, spironolactones, diuretics, etc., Qiliqiangxin capsules were used to treat 345 newly diagnosed DCM patients for 12 months. Compared with the control group, Qiliqiangxin capsules regulate inflammatory factors (reduce IFN- γ、 IL-17, TNF- α、 The imbalance between IL-4 (P<0.0001) and anti-inflammatory factors (increased IL-10, P<0.0001) significantly increased the effective rate of NT proBNP levels decreasing by ≥ 30% (68.4%: 50.0%, P=0.0005), reduced all-cause mortality rate by 2.2%, produced good inflammatory factor regulatory effects and improved patient cardiac function [3].

Qili Qiangxin Capsules are drugs for treating heart failure and immune regulation.

--Extracted from "Guidelines for the Diagnosis and Treatment of Dilated Cardiomyopathy in China"

Chinese Medical Association Cardiovascular Branch/Chinese Cardiomyositis and Cardiomyopathy Collaborative Group

Modern research shows that some traditional Chinese patent medicines and simple preparations have the potential to prevent or reverse ventricular remodeling, such as Qiliqiangxin capsule

The results of a multicenter, randomized, double-blind, placebo-controlled trial of Qili Qiangxin Capsules showed that the addition of Qili Qiangxin Capsules (4 capsules, 3 times a day, for 12 weeks) to standard anti-heart failure treatment significantly reduced the NT-proBNP levels in patients with chronic heart failure (NYHA heart function grading II-IV), significantly improved heart function and quality of life, increased LVEF, and 6-minute walking distance, Suitable for patients with chronic heart failure (NYHA heart function grading II to IV);

--Extracted from the "Guidelines for Reasonable Use of Drugs in Heart Failure (2nd Edition)"

National Health and Family Planning Commission Expert Committee on Rational Drug Use/China Pharmacists Association

C. A meta-analysis of the efficacy and safety of Qiliqiangxin capsules in the treatment of DHF showed that in 8 studies, Qiliqiangxin capsules significantly improved the E/A ratio (MD=0.16) and E/e 'ratio (MD=1.97) in patients with HFpEF (P0.01). The traditional Chinese medicine Qiliqiangxin improved ventricular diastolic function and increased the effectiveness of DHF treatment [6]. This expert group recommends the use of traditional Chinese medicine that can improve ventricular diastolic function to treat DHF, and recommends traditional Chinese patent medicines and simple preparations Qiliqiangxin capsule to treat DHF.

--Extracted from "Expert Recommendations for Early Prevention and Treatment of Diastolic Heart Failure"

China Heart Failure Center Alliance